|
市場調查報告書
毒性篩檢：2009年
Toxicity Screening 2009 Market Report
|
毒性篩檢：2009年 是由出版商Select Biosciences, Ltd.在2009年02月所出版的。
這份英文市場調查報告書包含370 pages 價格從美金2510起跳。
本報告書內容包括：毒性篩檢市場的最新動向、該領域的定性・定量分析結果、市場課題、新的動向、法規限制動向、各種篩檢技術概要等介紹等。內容綱要摘記如下：
第1章 市場概要
第2章 藥物開發的毒性篩檢：市場目前的動向及新興主題
- 藥物代謝過程
- ADME及毒性篩檢的各種生物學檢查系統
- 全球產業中企業底層發起的市場調查：定性・定量市場分析
第3章 hERG、LQTS、心室性心律不整
- 投藥QT延長症候群
- 為什麼hERG容易受到阻礙？
- 藥品產業的hERG阻礙是如何擴大的？
- 影響hERG的高度內容藥物詳細介紹
- hERG市場分析
- 法規限制
第4章 毒性篩檢產業動向：藥品產業的展望
- Genentech Inc
- Merck
- Abbott
- GlaxoSmithKline
- Eli-Lilly & Co
- AstraZeneca
- Celgene Corporation
- Bristol-Myers Squibb
第5章 附帶安全性訊息的藥物開發：產業預測
第6章 毒性產業環境：法規限制當局的展望
附錄
Abstract
This is the latest and most up-to-date Toxicity Screening Market Analysis
Report from Select Biosciences. This comprehensive report provides a
qualitative and quantitative analysis of the toxicity screening space, market
metrics, and thorough bottom-up based market trends obtained via detailed
market surveys administered by Select Biosciences to a worldwide industry
participant pool.
The report features perspectives from the pharmaceutical industry participants
engaged in toxicity screening providing a framework to understand the latest
industry trends in toxicity screening, the challenges, and the emerging
trends. This report is important to the industry as it combines
commercial/market analysis, regulatory trends in toxicity screening, as well
as the technical details of various screens, emerging classes of biomarkers,
and covers the all-important category of cardiotoxicity and LQTS-inducing
liability of compounds.
Extensive Worldwide Market Analyses Presented in this Report:
- Results and Analyses from Select Biosciences recent worldwide market
survey focusing upon the qualitative and quantitative trends in toxicity
screening. Areas of coverage include the market penetrance of various assay
types for ADME and Toxicity Screening, distribution of the industry with
respect to hits that are carried forward into toxicity screening
- Market Segmentation and Size
- The Process of Drug Metabolism
- Emerging Themes and Unmet Needs in the Toxicity Screening Marketplace
- Stem Cells for Toxicity Screening
- hERG, LQTS, and Torsades de Pointes: Role in Cardiotoxicity of
Pharmaceuticals: Technology and Market Trends
- Regulatory Landscape for Toxicity Screening: Regulatory Guidelines for
drug toxicity testing to assess hERG liability
- Developing Drugs with Safety Signals: Industry Perspectives
- Toxicity Industry Landscape: Perspectives from Regulatory Agencies
- Preclinical and Clinical non-QT Testing
- Cardiotoxicity and Troponins: Industry Perspectives
Table of Contents
Description of Chapters/Topics Covered
Chapter 1. Executive Overview of the Space
- Scope of this Report
- Market Definitions
- Market Segmentation
- Market Sizing
Chapter 2. Toxicity Screening in Drug Discovery: Current Trends and Emerging Themes in the Marketplace
- The Process of Drug Metabolism
- Various Biological Assay Systems for ADME and Toxicity Screening
- Bottom-up Market Survey of Worldwide Industry Participants: Qualitative
and Quantitative Market Analysis
Chapter 3. hERG, LQTS, Torsades de Pointes
- Drug-induced long QT syndrome (LQTS): Focus on hERG
- Why does hERG get blocked so easily?
- How widespread is hERG inhibition in the pharmaceutical industry
- Drug-acquired LQTS: Description of some high-profile drugs that affect hERG
- Analysis of the hERG marketplace
- Regulatory Section: ICH S7B and E14 guidelines
Chapter 4. Toxicity Screening Industry landscape: Perspectives from the Pharmaceutical Industry
- Genentech, Inc.
- Merck
- Abbott
- GlaxoSmithKline
- Eli-Lily & Co.
- AstraZeneca
- Celgene Corporation
- Bristol-Myers Squibb
Chapter 5. Developing Drugs with Safety Signals: Industry Perspectives
- University of Maryland
- Pfizer
- US FDA
Chapter 6. Toxicity Industry Landscape: perspectives from Regulatory Agencies
Appendix 1. Research Methodology
Appendix 2. hERG: Technology and Business
- Supporting Technical and Regulatory Trends Analysis
Appendix 3. Preclinical and Clinical non-QT Testing: Industry Perspectives
Appendix 4. Cardiotoxicity and Troponins: Industry Perspectives
|
